The effect of the alendronate on OPG/RANKL system in differentiated primary human osteoblasts.

Enjuanes, Anna; Ruiz-Gaspà, Silvia; Peris, Pilar; Ozalla, Dolores; Alvarez, Luisa; Combalia, Andrés; Martínez de Osaba, M Jesús; Monegal, Ana; Pares, Albert; Guañabens, Nuria

Enjuanes, Anna; Ruiz-Gaspà, Silvia; Peris, Pilar; Ozalla, Dolores; Alvarez, Luisa; Combalia, Andrés; Martínez de Osaba, M Jesús; Monegal, Ana; Pares, Albert; Guañabens, Nuria.

Affiliation

Enjuanes A; Metabolic Bone Diseases Unit, Department of Rheumatology, Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain. enjuanes@clinic.ub.es

Endocrine ; 37(2): 322-8, 2010 Apr.

Article in En | MEDLINE | ID: mdl-20960270

Subject(s)

Alendronate/pharmacology; Bone Density Conservation Agents/pharmacology; Osteoblasts/drug effects; Osteoprotegerin/genetics; RANK Ligand/genetics; Alkaline Phosphatase/metabolism; Cell Differentiation/drug effects; Cell Survival/drug effects; Cells, Cultured; Dose-Response Relationship, Drug; Enzyme Activation/drug effects; Gene Expression/drug effects; Humans; Osteoblasts/cytology; Osteoblasts/physiology; RNA, Messenger/metabolism; Vitamin D/pharmacology

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Osteoblasts / Alendronate / Bone Density Conservation Agents / RANK Ligand / Osteoprotegerin Limits: Humans Language: En Journal: Endocrine Journal subject: ENDOCRINOLOGIA Year: 2010 Document type: Article Affiliation country: Spain Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google